VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts.

不列颠哥伦比亚省维多利亚市--（商业新闻短讯）--ImmunoPrecise Antibodies Ltd.（以下简称“公司”或“IPA”）（纳斯达克：IPA），一家人工智能驱动的生物治疗研究和技术公司，于2024年11月15日（星期五）上午9:00至下午12:30（美国东部标准时间）在马萨诸塞州剑桥宣布其即将举行的TECHDAY活动的细节。

This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments..

这次独家聚会将重点介绍IPA在人工智能驱动设计、生物制剂创新和战略技术发展方面的最新进展。。

Highlights of TECHDAY:

TECHDAY的亮点：

Presentation by Dr. Dirk Van Hyfte: Dr. Van Hyfte will present “Accelerating Drug Discovery with LENSai: A Comprehensive Solution.” He will showcase LENSai, BioStrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence.

Dirk Van Hyfte博士的演讲：Van Hyfte博士将介绍“用LENSai加速药物发现：一个全面的解决方案”。他将展示LENSai，BioStrand的革命性平台，并讨论它如何通过整合生物技术，生物治疗学和人工智能来改变药物发现。

Key topics include using HYFT® Universal Fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with AI-driven insights..

。。

LENSai Demo: A live demonstration of the LENSai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through AI-driven insights.

LENSai演示：LENSai平台的现场演示，展示了其通过AI驱动的见解加速和增强治疗性抗体的发现和设计的能力。

Presentation by Dr. Shuji Sato: Dr. Sato will present IPA’s B Cell Discovery Platform and discuss its integration with the company’s advanced AI and NGS workflows for highly efficient hit expansion. This process includes:

佐藤博士的演讲：佐藤博士将介绍IPA的B细胞发现平台，并讨论其与公司先进的AI和NGS工作流程的集成，以实现高效的hit扩展。该过程包括：

Fast analysis of complete NGS repertoires

快速分析完整的NGS曲目

Multimodal feature extraction that combines sequence, structure, and large language model (LLM) embeddings to deliver enhanced insights into sample diversity.

多模态特征提取，结合序列，结构和大型语言模型（LLM）嵌入，以增强对样本多样性的了解。

Add-ons that complement outputs from phage display, B-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders.

。

Fireside Chat: Disruptive Dialogue: Empowering Drug Discovery Through Seamless Data Integration and AI-Powered Insights

炉边聊天：颠覆性对话：通过无缝数据集成和人工智能支持的见解增强药物发现能力

Participants:

与会者：

Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)

BioStrand（IPA）创新主管兼联合创始人Dirk Van Hyfte博士

Jeff Fried, Director of Platform Strategy and Innovation, InterSystems

Jeff Fried，InterSystems平台战略与创新总监

This discussion will explore how vector search intelligence is at the core of the LENSai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity.

本次讨论将探讨向量搜索智能如何成为LENSai平台的核心，与InterSystems IRIS数据平台无缝集成，以提供精确、可扩展的解决方案，加速抗体发现，提高准确性，增加候选多样性。

AI-Driven Drug Discovery Summit USA 2024

2024年美国人工智能驱动的药物发现峰会

Additionally, earlier that same week at the AI-Driven Drug Discovery Summit USA 2024, IPA will participate in another fireside chat titled Beyond conventional biologics: the intersection of machine learning and biological engineering to invent.

此外，同一周早些时候，在2024年美国人工智能驱动的药物发现峰会上，IPA将参加另一场名为“超越传统生物制剂：机器学习与生物工程的交叉发明”的炉边聊天。

Participants at the AI-Driven Drug Discovery Summit USA 2024:

2024年美国人工智能驱动药物发现峰会的参与者：

Adam Root, Vice President and Head of Protein Sciences, Generate Biomedicines

副总裁兼蛋白质科学负责人亚当·罗特（AdamRoot）从事生物医学研究

Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)

BioStrand（IPA）创新主管兼联合创始人Dirk Van Hyfte博士

The chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development.

聊天将重点讨论人工智能和机器学习与湿实验室基础设施的集成，以加速生物制剂的开发。

A recorded webcast of the TECHDAY presentations will be available in the Investors section of the IPA website under 'Events and Presentations' at ir.ipatherapeutics.com.

TECHDAY演示文稿的录制网络广播将在IPA网站的投资者部分的ir.ipatherapeutics.com的“事件和演示”下提供。

Interested in joining us for this exclusive TECHDAY experience? Space is limited - secure your spot by contacting Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com

有兴趣加入我们的TECHDAY独家体验吗？空间有限-请联系Quantum Media的MBA博士Jennifer K.Zimmons，以确保您的位置：jen@quantum-corp.com

About ImmunoPrecise Antibodies Ltd.

关于ImmunoPrecise Antibodies Ltd。

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.

ImmunoPrecise Antibodies Ltd.是一家生物技术公司，通过一系列专有和专利技术利用多组学建模和复杂的人工智能。该公司拥有一套完整的端到端功能，以支持治疗性抗体的开发，并以解决非常复杂的行业挑战而闻名。

IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”)..

IPA在北美和欧洲有多家子公司，包括Talem Therapeutics LLC、BioStrand BV、ImmunoPrecise Antibodies（Canada）Ltd.和ImmunoPrecise Antibodies（Europe）B.V.（统称“IPA家族”）等实体。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved.

本新闻稿包含适用的美国证券法和加拿大证券法所指的前瞻性声明。前瞻性陈述通常通过使用“预期”、“估计”、“打算”、“预期”或“相信”等词语来识别，或者通过这些词语和短语的变体来识别，或者声明某些行动、事件或结果“可能”、“将会”、“可能”或“将要”采取、发生或实现。

Forward-looking statements include, but are not limited to, statements regarding the capabilities, impact and results expected from BioStrand’s LENSai platform. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

前瞻性声明包括但不限于有关BioStrand LENSai平台的功能、影响和预期结果的声明。虽然公司认为我们对每项前瞻性陈述都有合理的依据，但我们提醒您，这些陈述是基于我们目前已知的事实和因素以及我们对未来的预期，我们对此无法确定。

Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States, Canada or internationally.

由于我们无法控制的因素，包括与市场和其他条件相关的风险和不确定性，以及美国、加拿大或国际上的一般经济、行业或政治条件的影响，我们未来的实际结果可能与我们的预期存在重大差异。

You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. These forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future..

您还应查阅我们向加拿大和美国证券委员会提交的季度和年度文件，以获取有关风险和不确定性的更多信息。这些前瞻性声明仅在本新闻稿发布之日起生效，公司没有义务以任何理由修改或更新任何前瞻性声明，即使将来有新信息可用。。

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致本文所述的实际结果、业绩或成就与前瞻性陈述所表达或暗示的任何未来结果、业绩或成就存在重大差异。

Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar).

由于许多因素和风险，实际结果可能与目前预期的结果存在重大差异，如公司截至2024年4月30日的20-F表年度报告所述（可在www.sedarplus.ca的公司SEDAR+简介和www.sec.gov/EDGAR的EDGAR简介中查看）。

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release.

如果出现一个或多个此类风险或不确定性，或者前瞻性声明的假设被证明不正确，则实际结果、绩效或成就可能与本新闻稿中包含的前瞻性声明所明示或暗示的结果、绩效或成就存在重大差异。

Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law..

因此，读者不应过度依赖本新闻稿中包含的前瞻性陈述。本新闻稿中包含的前瞻性声明自本新闻稿发布之日起作出，因此，在此日期后可能会发生变化。除适用法律要求外，公司不承担更新或修改我们或代表我们不时做出的任何前瞻性声明（无论是书面还是口头）的任何义务。。